Tdspharm Co., Ltd. researches (464280) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Tdspharm Co., Ltd. researches stock KRW 12,630, price KRW 4,210, upside +200.0%, quality 42 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
27‑month range 4,210 KRW – 52,000 KRW · fair‑value band 8,841 KRW – 15,822 KRW · the 4,210 KRW price screens below the 12,630 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Tdspharm Co., Ltd. researches in your weekly email
Every Wednesday you see whether Tdspharm Co., Ltd. researches is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tdspharm Co., Ltd. researches, develops, and produces pharmaceuticals and cosmetics in South Korea and internationally. It offers general medicines, prescription drugs, and non-medicinal products. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Stock analysis
Tdspharm Co., Ltd. researches (464280) currently trades at 4,210 KRW, while our model-based Fair Value estimate is 12,630 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 13,710 KRW per share, and 11 of the 12 models we run sit above the 4,210 KRW price.
Bear case: the Asset-Based group reads lowest at 3,489 KRW, and 1 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: 8,841 KRW (bear) to 15,822 KRW (bull), the price of 4,210 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tdspharm Co., Ltd. researches reported revenue of 27.6B KRW in FY2025 versus 19.8B KRW in FY2021, a compound +8.7%/yr. Reported net income was 4.3B KRW in FY2025, compounding +20.0%/yr from FY2021.
Key figures
Market cap 22.9B KRW (≈ $16.9M) Micro · P/E ratio 4.4 · P/S ratio 0.70 · EPS (TTM) 974.67 KRW · Net margin 15.7% · Return on equity 12.2% · Return on assets (EBIT) 10.0% (5-year average) · Operating margin 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 60% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 200%, 464280 screens cheaper than that median.
Fair Value models
Bear8,841 KRWFair Value 12,630 KRWBull15,822 KRW
Price 4,210 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (835.82 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 14%
Compare Tdspharm Co., Ltd. researches with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)12.2% · Above median
Return on assets7.9% · Above median
Net margin (12 months)15.7% · Above median
Operating margin (12 months)12.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)44.7% · Top 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tdspharm Co., Ltd. researches (464280) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 12,630 KRW versus a price of 4,210 KRW, about +200% upside (undervalued).
What is the fair value of 464280?
Our model-based fair value for Tdspharm Co., Ltd. researches is 12,630 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 4,210 KRW.
What is the quality score of 464280?
Tdspharm Co., Ltd. researches has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tdspharm Co., Ltd. researches (464280)?
Our model-based price target is the fair value of 12,630 KRW (as of Nov 3, 2026) from 12 valuation models. Cautious scenario 8,841 KRW, optimistic scenario 15,822 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Tdspharm Co., Ltd. researches stock forecast for 2026?
Our models put fair value at 12,630 KRW, about +200% upside versus a price of 4,210 KRW (undervalued). Cautious scenario 8,841 KRW, optimistic scenario 15,822 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Tdspharm Co., Ltd. researches (464280)?
Tdspharm Co., Ltd. researches reported trailing-twelve-month revenue of about 32.9B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Tdspharm Co., Ltd. researches (464280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tdspharm Co., Ltd. researches it is 12,630 KRW per share (as of Nov 3, 2026), against a price of 4,210 KRW. It is the blended result of 12 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Tdspharm Co., Ltd. researches stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 464280 trades below its calculated fair value: price 4,210 KRW, fair value 12,630 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 464280?
No. The price is what the market pays today (4,210 KRW); the fair value is what the company's own numbers justify (12,630 KRW). For Tdspharm Co., Ltd. researches the two are 8,420 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Tdspharm Co., Ltd. researches worth?
The market values Tdspharm Co., Ltd. researches at about 22.9B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 4,210 KRW; our models calculate a fair value of 12,630 KRW per share.
What do the bullish and bearish scenarios say about 464280?
Our models span a range for Tdspharm Co., Ltd. researches: cautious scenario 8,841 KRW, base 12,630 KRW, optimistic 15,822 KRW per share (as of Nov 3, 2026, price 4,210 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 464280?
Tdspharm Co., Ltd. researches trades at a price-to-earnings ratio of 4.4 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 12,630 KRW is built from several models across several years. Other multiples: P/B 0.5, P/S 0.7, EV/EBITDA 3.4.
How solid is the balance sheet of Tdspharm Co., Ltd. researches (464280)?
Balance-sheet figures for Tdspharm Co., Ltd. researches (as of Nov 3, 2026): return on equity 12.2%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 464280 from its 52-week high?
Tdspharm Co., Ltd. researches trades at 4,210 KRW, about 60% below its 52-week high of 10,500 KRW and at the low of 4,210 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 12,630 KRW is for.
Which stocks are comparable to Tdspharm Co., Ltd. researches?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tdspharm Co., Ltd. researches stock attractive at the current price?
The data as of Nov 3, 2026: price 4,210 KRW, calculated fair value 12,630 KRW (+200%), Quality Score 42/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 464280 calculated?
We run Tdspharm Co., Ltd. researches through 12 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 12,630 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Tdspharm Co., Ltd. researches currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tdspharm Co., Ltd. researches (464280)?
The closing price on Nov 6, 2026 was 4,210 KRW. Our model-based fair value is 12,630 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tdspharm Co., Ltd. researches right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (8,841 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Tdspharm Co., Ltd. researches
How large is the market capitalisation of Tdspharm Co., Ltd. researches (464280)?
The market capitalisation of Tdspharm Co., Ltd. researches is 22.9B KRW (≈ $16.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tdspharm Co., Ltd. researches (464280)?
The price-to-sales ratio of Tdspharm Co., Ltd. researches is 0.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tdspharm Co., Ltd. researches (464280)?
Earnings per share at Tdspharm Co., Ltd. researches are 974.67 KRW (price ÷ EPS = P/E 4.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tdspharm Co., Ltd. researches (464280)?
The net margin of Tdspharm Co., Ltd. researches is 15.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tdspharm Co., Ltd. researches (464280)?
The return on equity (ROE) of Tdspharm Co., Ltd. researches is 12.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tdspharm Co., Ltd. researches (464280)?
On an EBIT basis the return on assets of Tdspharm Co., Ltd. researches is 10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tdspharm Co., Ltd. researches (464280)?
The operating margin of Tdspharm Co., Ltd. researches is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tdspharm Co., Ltd. researches (464280)?
Revenue at Tdspharm Co., Ltd. researches is growing +44.7% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tdspharm Co., Ltd. researches (464280)?
Earnings per share at Tdspharm Co., Ltd. researches are growing +11.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tdspharm Co., Ltd. researches (464280) generate?
The free cash flow of Tdspharm Co., Ltd. researches is −9.1B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tdspharm Co., Ltd. researches (464280) carry?
The net debt of Tdspharm Co., Ltd. researches is 6.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tdspharm Co., Ltd. researches in the live analysis
One click puts Tdspharm Co., Ltd. researches on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026